Reasons to Hold Hinge Health Stock in Your Portfolio for Now

Hinge Health raised its 2026 revenue guidance to $856-$860 million after Q2 revenue jumped 53% to $212.8 million. The digital musculoskeletal care platform is diversifying beyond its core offering, now serving 450 clients and 5 million lives through its Migraine Care product while pursuing a $105 million acquisition of Cylinder Health to enter the gastrointestinal care market.

Zacks Investment Research notes HNGE maintains a 30.6% expected growth rate, but the expansion strategy carries near-term margin pressure. Product development and integration costs related to the Cylinder Health deal will weigh on profitability as the company executes its multi-condition strategy.

The raised guidance signals management confidence in cross-selling into its existing employer and health plan client base. The Migraine Care penetration across 5 million covered lives demonstrates early traction in adjacent chronic condition markets, while the GI acquisition accelerates a third revenue stream rather than building in-house.